High D-dimer levels are associated with poor prognosis in cancer patients

Haematologica

Volumn 97, Issue 8, 2012, Pages 1158-1164

  Ay, Cihan ^a   Dunkler, Daniela ^a   Pirker, Robert ^b   Thaler, Johannes ^a   Quehenberger, Peter ^a   Wagner, Oswald ^a   Zielinski, Christoph ^b   Pabinger, Ingrid ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Clinical Division of Oncology   (Austria)

Author keywords

D dimer; Hemostasis; Prognosis; Thrombosis; Tumor; Venous thromboembolism

Indexed keywords

D DIMER;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; COHORT ANALYSIS; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HUMAN; LATEX AGGLUTINATION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROSPECTIVE STUDY; PROTEIN LOCALIZATION; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

AGED; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84863493607     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.054718     Document Type: Article

References (42)

1. Lyman GH, Khorana AA. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol. 2009;27(29):4821-6.
2. Edwards RL, Rickles FR, Moritz TE, Henderson WG, Zacharski LR, Forman WB, et al. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol. 1987;88(5):596-602.
3. Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol. 2009;22(1): 49-60.
4. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96(10):3302-9.
5. Malik G, Knowles LM, Dhir R, Xu S, Yang S, Ruoslahti E, et al. Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion. Cancer Res. 2010;70(11):4327-34.
6. Jain S, Harris J, Ware J. Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol. 2010;30(12):2362-7.
7. Thompson WD, Smith EB, Stirk CM, Marshall FI, Stout AJ, Kocchar A. Angiogenic activity of fibrin degradation products is located in fibrin fragment E. J Pathol. 1992;168(1):47-53.
8. Pabinger I, Ay C. Biomarkers and venous thromboembolism. Arterioscler Thromb Vasc Biol. 2009;29(3):332-6.
9. Lippi G, Franchini M, Targher G, Favaloro EJ. Help me, Doctor! My D-dimer is raised. Ann Med. 2008;40(8):594-605.
10. Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009;27 (25):4124-9.
11. Arpaia G, Carpenedo M, Verga M, Mastrogiacomo O, Fagnani D, Lanfredini M, et al. D-dimer before chemotherapy might predict venous thromboembolism. Blood Coagul Fibrinolysis. 2009;20(3):170-5.
12. Ay C, Pabinger I. Tests predictive of thrombosis in cancer. Thromb Res. 2010;125 (Suppl 2):S12-5.
13. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355(17):1780-9.
14. Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Iglehart JD, et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol. 2000;18(3):600-8.
15. Batschauer AP, Figueiredo CP, Bueno EC, Ribeiro MA, Dusse LM, Fernandes AP, et al. D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol. 2010;21(6):1267-72.
16. Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer. 2002;86(3):389-95.
17. Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol. 2001;31(8):388-94.
18. Blackwell K, Hurwitz H, Liebérman G, Novotny W, Snyder S, Dewhirst M, et al. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer. 2004;101(1):77-82.
19. Altiay G, Ciftci A, Demir M, Kocak Z, Sut N, Tabakoglu E, et al. High plasma D-dimer level is associated with decreased survival in patients with lung cancer. Clin Oncol (R Coll Radiol). 2007;19(7):494-8.
20. Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer. 2003;97(12):3044-52.
21. Taguchi O, Gabazza EC, Yasui H, Kobayashi T, Yoshida M, Kobayashi H. Prognostic significance of plasma D-dimer levels in patients with lung cancer. Thorax. 1997;52(6):563-5.
22. Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008;112(7):2703-8.
23. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377-82.
24. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343-6.
25. Team RDC. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2009:ISBN 3-900051-07-0, http://www.R-project.org.
26. Hoke M, Dieckmann K, Koppensteiner R, Schillinger M, Marosi C, Mlekusch W. Prognostic value of plasma d-dimer levels in patients with glioblastoma multiforme Results from a pilot study. Wien Klin Wochenschr. 2011;123(7-8):199-203.
27. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458-64.
28. Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol. 2007; 25(1):70-6.
29. Alcalay A, Wun T, Khatri V, Chew HK, Harvey D, Zhou H, et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol. 2006;24(7):1112-8.
30. Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol. 2009;27(29):4902-11.
31. Schutgens RE, Haas FJ, Biesma DH. Reduced efficacy of clinical probability score and D-dimer assay in elderly subjects suspected of having deep vein thrombosis. Br J Haematol. 2005;129(5):653-7.
32. Mirshahi SS, Pujade-Lauraine E, Soria C, Mirshahi M, Fretault J, Bernadou A, et al. D-dimer and CA 125 levels in patients with ovarian cancer during antineoplastic therapy. Prognostic significance for the success of anti-cancer treatment. Cancer. 1992;69 (9):2289-92.
33. Rose PG, Terrien JM, Baker S. Plasma D-dimer and peritoneal CA-125 levels as predictors of disease status in ovarian carcinoma. J Surg Oncol. 1994;56(3):168-71.
34. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol. 2009;27(29):4834-8.
35. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood. 2004;104(2):397-401.
36. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105(1):178-85.
37. Cronin CG, Lohan DG, Keane M, Roche C, Murphy JM. Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. AJR Am J Roentgenol. 2007;189(1):162-70.
38. Gladish GW, Choe DH, Marom EM, Sabloff BS, Broemeling LD, Munden RF. Incidental pulmonary emboli in oncology patients: prevalence, CT evaluation, and natural history. Radiology. 2006;240(1):246-55.
39. Dentali F, Ageno W, Pierfranceschi MG, Imberti D, Malato A, Nitti C, et al. Prognostic relevance of asymptomatic venous thromboembolism in patients with cancer. J Thromb Haemost. 2011;9(5):1081-3.
40. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339-46.
41. Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4(3):529-35.
42. Kanz R, Vukovich T, Vormittag R, Dunkler D, Ay C, Thaler J, et al. Thrombosis risk and survival in cancer patients with elevated Creative protein. J Thromb Haemost. 2011;9(1):57-63.